Incyte (NASDAQ:INCY) Stock Price Up 8.6% After Better-Than-Expected Earnings

Incyte Corporation (NASDAQ:INCY) shares rose 8.6% during mid-day trading on Tuesday after the company announced better than expected quarterly earnings. The company traded as high as $128.28 and last traded at $129.1450. Approximately 2,326,434 shares traded hands during mid-day trading, an increase of 32% from the average daily volume of 1,757,770 shares. The stock had previously closed at $118.87.

The biopharmaceutical company reported $3.09 earnings per share for the quarter, topping analysts’ consensus estimates of $2.20 by $0.89. The company had revenue of $1.67 billion during the quarter, compared to analysts’ expectations of $1.50 billion. Incyte had a return on equity of 26.66% and a net margin of 26.71%.The business’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.57 earnings per share.

Key Stories Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Quarterly results topped expectations. Incyte reported second-quarter revenue of $1.67 billion, up 37.7% year over year and above the $1.50 billion consensus estimate. Adjusted EPS of $3.09 also exceeded the $2.20 consensus, compared with $1.57 a year earlier. Incyte Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Opzelura and oncology products drove growth. Opzelura sales surged 173% to $450 million, including a $246 million one-time, non-cash benefit related to the company’s CMS settlement. Hematology and oncology portfolio sales rose 69% to $222 million, while Jakafi and Jakafi XR sales increased 7% to $817 million. Opzelura and Cancer Portfolio Fuel Strong Quarter
• Positive Sentiment: Incyte raised its 2026 sales outlook. The company increased full-year total net sales guidance to approximately $5.13 billion-$5.26 billion, citing the CMS agreement and product growth. It also expects 10 clinical data readouts during the second half of 2026, providing potential catalysts. Incyte Lifts Annual Revenue Forecast
• Neutral Sentiment: Valuation and momentum remain supportive. Zacks characterized Incyte as a strong value stock, while the shares have risen substantially and trade near their 12-month high. Why Incyte Is a Strong Value Stock
• Negative Sentiment: Full-year guidance trails expectations. The $5.13 billion-$5.26 billion revenue outlook remains below the roughly $5.6 billion consensus estimate, potentially limiting upside despite the quarterly beat.
• Negative Sentiment: Pipeline and valuation concerns remain. Incyte discontinued a Phase 1 JAK inhibitor to focus on next-generation programs, reducing one development opportunity. Separately, an analyst downgraded the stock from Buy to Hold after its 93% rally, and the shares underperformed some peers despite gaining. Incyte Ditches Phase 1 JAK Inhibitor Incyte Rating Downgrade

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $140.00 target price on shares of Incyte in a research report on Tuesday, July 21st. Truist Financial boosted their price objective on Incyte from $103.00 to $105.00 and gave the stock a “hold” rating in a research report on Monday, June 22nd. Citigroup reaffirmed a “market perform” rating on shares of Incyte in a report on Wednesday, July 15th. Morgan Stanley lifted their price target on Incyte from $103.00 to $104.00 and gave the stock an “equal weight” rating in a research report on Thursday. Finally, JPMorgan Chase & Co. upped their price target on Incyte from $105.00 to $110.00 and gave the stock a “neutral” rating in a report on Thursday, July 23rd. Eight research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $111.10.

Institutional Investors Weigh In On Incyte

Institutional investors and hedge funds have recently made changes to their positions in the company. Jacobi Capital Management LLC grew its stake in Incyte by 0.9% during the fourth quarter. Jacobi Capital Management LLC now owns 10,613 shares of the biopharmaceutical company’s stock worth $1,048,000 after buying an additional 99 shares during the last quarter. Oregon Public Employees Retirement Fund raised its position in shares of Incyte by 0.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 18,870 shares of the biopharmaceutical company’s stock worth $1,864,000 after acquiring an additional 100 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in Incyte by 7.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,628 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 113 shares during the period. Bank of Nova Scotia lifted its holdings in Incyte by 0.7% in the second quarter. Bank of Nova Scotia now owns 17,041 shares of the biopharmaceutical company’s stock valued at $1,160,000 after buying an additional 124 shares during the period. Finally, Perbak Capital Partners LLP boosted its position in shares of Incyte by 2.5% in the 3rd quarter. Perbak Capital Partners LLP now owns 5,298 shares of the biopharmaceutical company’s stock worth $449,000 after purchasing an additional 129 shares during the last quarter. Institutional investors and hedge funds own 96.97% of the company’s stock.

Incyte Stock Performance

The stock has a fifty day simple moving average of $107.30 and a 200-day simple moving average of $101.72. The stock has a market cap of $25.58 billion, a P/E ratio of 18.15, a PEG ratio of 1.06 and a beta of 0.76. The company has a quick ratio of 3.60, a current ratio of 3.68 and a debt-to-equity ratio of 0.01.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.